SCHEMBL4195553

SCHEMBL4195553

CCN(CC)c1ccc(N(Cc2cccnc2)c2ccc(OC)c(OC3CCCO3)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.44
PDE4B Q07343 5/20 0.44
PDE4C Q08493 4/20 0.44
PDE4D Q08499 4/20 0.44
PTAFR P25105 7/20 0.40
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
FGFR1 P11362 1/20 0.37
FGFR2 P21802 1/20 0.37
FGFR4 P22455 1/20 0.37
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37
QPCT Q16769 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1156850 0.92 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DPTAFR
SCHEMBL1157495 0.91 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DPTAFR
SCHEMBL4195871 0.90 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DPTAFR
SCHEMBL4204569 0.89 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DPTAFR
SCHEMBL4188495 0.89 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DPTAFR
SCHEMBL4198462 0.87 PDE4B (0.54) PDE4APDE4BPDE4CPDE4DPTAFR
SCHEMBL4193854 0.87 PDE4B (0.48) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL4193007 0.87 PDE4B (0.42) PDE4APDE4BPDE4CPDE4DPTAFR
SCHEMBL4201021 0.87 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DPTAFR
SCHEMBL1157475 0.87 PDE4B (0.43) PDE4APDE4BPDE4CPDE4DPTAFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US claimed
EP-1539697-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS Memory Pharmaceutical Corporation (US) 2005-06-15 EP claimed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US claimed
WO-2004009552-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO claimed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.